We support all efforts to increase the awareness and understanding of COPD and its management. We salute the US COPD Coalition and National COPD Awareness Month.
Allentown, Pennsylvania (PRWEB) October 30, 2012
Spiro PD Personal Spirometer manufacturer PMD Healthcare is proud to join the observance of National Chronic Obstructive Pulmonary Disease (COPD) Month.
Sponsored by the US COPD Coalition, the month-long observance throughout November offers the opportunity for organizations, health care professionals, patients, families, and caregivers across the country to increase the overall awareness of COPD.
Patients with COPD and other respiratory conditions – including asthma, bronchitis, emphysema, cystic fibrosis (CF), and lung transplants – are using Spiro PD Personal Spirometer to track lung function trends. This helps patients anticipate and prevent respiratory disease exacerbations, which may reduce expensive emergency room visits and hospital stays. It also helps prevent readmissions, so hospitals can avoid costly Medicare penalties.
Plus, the innovative telemedicine feature of Spiro PD permits people with respiratory conditions to easily upload their data to their computer and share it with their doctors between office visits. The telemedicine feature is proving particularly valuable for people who are physically challenged or live a long distance from their doctors.
According to a Johns Hopkins University study, home spirometry detected a decline in lung function 15.6 days before patients felt symptoms and sought medical care.(1) Spiro PD’s ability to note early detection of decreased lung function can catch problems before they worsen and keep chronic respiratory patients out of hospitals.
Says Wayne Meng, Founder, Chief Executive Officer, and President of PMD Healthcare, the maker of Spiro PD, “We support all efforts to increase the awareness and understanding of COPD and its management. We salute the US COPD Coalition and National COPD Awareness Month.”
For more information about all the advantages that Spiro PD offers people with COPD and other respiratory conditions, please visit http://www.SpiroPD.com.
About Spiro PD
“Spiro" stands for spirometer, a device used to measure air entering and leaving the lungs; "PD" stands for personal device. Spiro PD is the first personal spirometer that enables people with lung diseases – COPD, asthma, CF, and lung transplants – to easily and accurately monitor their breathing anytime and anywhere.
Spiro PD tracks lung function trends to help patients anticipate and prevent respiratory disease exacerbations, which helps reduce expensive emergency room visits and hospital stays. According to a study conducted at Johns Hopkins University, home spirometry detected decreased lung function 15.6 days before patients felt symptoms and sought medical care.(1)
Spiro PD enhances medication adherence. The medication alarm helps patients remember to take their medicine. The medication history provides a time stamp to show doctors that patients have been following their therapy.
Spiro PD also allows patients to set alarms reminding them to perform spirometry tests and do breathing exercises. Plus, patients can quickly upload data to their computer and share it with their doctor.
Spiro PD is cleared by the FDA for home use by the patient to test lung function in children, adolescents, and adults. Many insurance companies cover the cost of Spiro PD.
Spiro PD meets American Thoracic Society (ATS) and European Respiratory Society (ERS) standards. Spiro PD is also certified with the CE mark for the European Union (EU).
For more information, visit http://www.SpiroPD.com.
About PMD Healthcare, Inc.
PMD Healthcare, manufacturer of Spiro PD, is dedicated to creating innovative, easy-to-use, portable, and affordable personal medical devices that empower people worldwide to improve their healthcare and quality of life. For more information about PMD Healthcare and Spiro PD, please visit http://www.SpiroPD.com.
1. West NE, Boyle MP, Mogayzel PJ, Riekert KA, Lechtzin N. The ability of home spirometry and symptom monitoring to predict exacerbations in cystic fibrosis. Pediatric Pulmonology 2009; Vol. 34, S32 “Poster Session Abstract” poster 376.